A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Eosinophilic Esophagitis

Date Added
February 11th, 2020
PRO Number
Pro00092458
Researcher
Kelli Williams

List of Studies

Keywords
Esophagus, Pediatrics
Summary

The main purpose of this study is to see if taking dupilumab is effective in treating Eosinophilic Esophogitis (EoE). The study will determine if dupilumab is an effective treatment compared with placebo in adult and adolescent patients. Dupilumab is administered through a subcutaneous injection (shot). Dupilumab is is an investigational drug, which means that it is not yet approved to treat EoE. Participation in the study will last up to 48 weeks.

Institution
MUSC
Recruitment Contact
Susannah Wakefield
843-792-8352
wakefies@musc.edu



-- OR --